Baselga J, Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, **23:**2445–2459. ArticlePubMedCAS Google Scholar
Omuro AM, Faivre S, Raymond E: Lessons learned in the development of targeted therapy for malignant gliomas. Mol Cancer Ther 2007, **6:**1909–1919. ArticlePubMedCAS Google Scholar
Deeken JF, Loscher W: The blood-brain barrier and cancer: transporters, treatment, and trojan horses. Clin Cancer Res 2007, **13:**1663–1674. ArticlePubMedCAS Google Scholar
Colgan OC, Collins NT, Ferguson G, et al.: Influence of basolateral condition on the regulation of brain microvascular endothelial tight junction properties and barrier function. Brain Res 2008, **1193:**84–92. ArticlePubMedCAS Google Scholar
Calatozzolo C, Gelati M, Ciusani E, et al.: Expression of drug resistance proteins pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 2005, **74:**113–121. ArticlePubMedCAS Google Scholar
Szabo D, Keyzer H, Kaiser HE, Molnar J: Reversal of multidrug resistance of tumor cells. Anticancer Res 2000, **20:**4261–4274. PubMedCAS Google Scholar
Bihorel S, Camenisch G, Lemaire M, Scherrmann JM: Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar. Pharm Res 2007, **24:**1720–1728. ArticlePubMedCAS Google Scholar
de Vries NA, Zhao J, Kroon E, et al.: P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res 2007, **13:**6440–6449. ArticlePubMedCAS Google Scholar
Szakacs G, Paterson JK, Ludwig JA, et al.: Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, **5:**219–234. ArticlePubMedCAS Google Scholar
Grossman SA, Hochberg F, Fisher J, et al.: Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The new approaches to brain tumor therapy. Cancer Chemother Pharmacol 1998, **42:**118–126. ArticlePubMedCAS Google Scholar
Jones AR, Shusta EV: Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 2007, **24:**1759–1771. ArticlePubMedCAS Google Scholar
Groothuis DR: The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol 2000, **2:**45–59. ArticlePubMedCAS Google Scholar
Xia CF, Zhang Y, Zhang Y, et al.: Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm Res 2007, **24:**2309–2316. ArticlePubMedCAS Google Scholar
Lu W, Zhang Y, Tan YZ, et al.: Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. J Control Release 2005, **107:**428–448. ArticlePubMedCAS Google Scholar
Muldoon LL, Soussain C, Jahnke K, et al.: Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, **25:**2295–2305. ArticlePubMedCAS Google Scholar
Mohile NA, Abrey LE: Primary central nervous system lymphoma. Neurol Clin 2007, **25:**1193–1207. ArticlePubMed Google Scholar
Vinolas N, Gil M, Verger E, et al.: Pre-irradiation semi-intensive chemotherapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs 2002, **13:**163–167. ArticlePubMedCAS Google Scholar
Dropcho EJ, Rosenfeld SS, Vitek J, et al.: Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol 1998, **36:**191–198. ArticlePubMedCAS Google Scholar
Ashby LS, Shapiro WR: Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study. J Neurooncol 2001, **51:**67–86. ArticlePubMedCAS Google Scholar
Fortin D, Desjardins A, Benko A, et al.: Enhanced chemotherapy delivery by intraarterial infusion and blood-brain barrier disruption in malignant brain tumors: the Sherbrooke experience. Cancer 2005, **103:**2606–2615. ArticlePubMed Google Scholar
Remsen LG, Trail PA, Hellstrom I, et al.: Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 2000, **46:**704–709. ArticlePubMedCAS Google Scholar
Kraemer DF, Fortin D, Doolittle ND, Neuwelt EA: Association of total dose intensity of chemotherapy in primary central nervous system lymphoma (human non-acquired immunodeficiency syndrome) and survival. Neurosurgery 2001, **48:**1033–1040; discussion 1040–1041. ArticlePubMedCAS Google Scholar
Jahnke K, Kraemer DF, Knight KR, et al.: Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. Cancer 2008, **112:**581–588. ArticlePubMed Google Scholar
Cao Y, Tsien CI, Shen Z, et al.: Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol 2005, **23:**4127–4136. ArticlePubMed Google Scholar
van Vulpen M, Kal HB, Taphoorn MJ, El-Sharouni SY: Changes in blood-brain barrier permeability induced by radiotherapy: implications for timing of chemotherapy? [review]. Oncol Rep 2002, **9:**683–688. PubMed Google Scholar
Ma J, Pulfer S, Li S, et al.: Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001, **61:**5491–5498. PubMedCAS Google Scholar
Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, **307:**58–62. ArticlePubMedCAS Google Scholar
Brem H, Piantadosi S, Burger PC, et al.: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The polymer-brain tumor treatment group. Lancet 1995, **345:**1008–1012. ArticlePubMedCAS Google Scholar
Westphal M, Hilt DC, Bortey E, et al.: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 2003, **5:**79–88. ArticlePubMedCAS Google Scholar
Fung LK, Ewend MG, Sills A, et al.: Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 1998, **58:**672–684. PubMedCAS Google Scholar
Weingart J, Grossman SA, Carson KA, et al.: Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J Clin Oncol 2007, **25:**399–404. ArticlePubMedCAS Google Scholar
Olivi A, Grossman SA, Tatter S, et al.; New Approaches to Brain Tumor Therapy CNS Consortium: Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol 2003, **21:**1845–1849. ArticlePubMedCAS Google Scholar
Ewend MG, Brem S, Gilbert M, et al.: Treatment of single brain metastasis with resection, intracavity carmustine polymer wafers, and radiation therapy is safe and provides excellent local control. Clin Cancer Res 2007, **13:**3637–3641. ArticlePubMedCAS Google Scholar
Vukelja SJ, Anthony SP, Arseneau JC, et al.: Phase 1 study of escalating-dose OncoGel (ReGel/paclitaxel) depot injection, a controlled-release formulation of paclitaxel, for local management of superficial solid tumor lesions. Anticancer Drugs 2007, **18:**283–289. ArticlePubMedCAS Google Scholar
Sheleg SV, Korotkevich EA, Zhavrid EA, et al.: Local chemotherapy with cisplatin-depot for glioblastoma multiforme. J Neurooncol 2002, **60:**53–59. ArticlePubMed Google Scholar
Patel SJ, Shapiro WR, Laske DW, et al.: Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery 2005, **56:**1243–1252; discussion 1252–1253. ArticlePubMed Google Scholar
Kunwar S, Prados MD, Chang SM, et al.: Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the cintredekin besudotox intraparenchymal study group. J Clin Oncol 2007, **25:**837–844. ArticlePubMedCAS Google Scholar
Grossman SA, Trump DL, Chen DC, et al.: Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography. Am J Med 1982, **73:**641–647. ArticlePubMedCAS Google Scholar
Mamelak AN, Rosenfeld S, Bucholz R, et al.: Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 2006, **24:**3644–3650. ArticlePubMedCAS Google Scholar
Reddy GR, Bhojani MS, McConville P, et al.: Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006, **12:**6677–6686. ArticlePubMedCAS Google Scholar
Yoshida J, Mizuno M: Clinical gene therapy for brain tumors. Liposomal delivery of anticancer molecule to glioma. J Neurooncol 2003, **65:**261–267. ArticlePubMed Google Scholar
Shao K, Hou Q, Duan W, et al.: Intracellular drug delivery by sulfatide-mediated liposomes to gliomas. J Control Release 2006, **115:**150–157. ArticlePubMedCAS Google Scholar
de Lange EC, de Vries JD, Zurcher C, et al.: The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain. Pharm Res 1995, **12:**1924–1931. ArticlePubMed Google Scholar
Olson J, Blakeley J, Grossman SA, et al.: Differences in the distribution of methotrexate into high grade gliomas following intravenous administration, as monitored by microdialysis, are associated with blood brain barrier integrity [abstract]. J Clin Oncol 2006, **24:**1548. Google Scholar
Portnow J, Badie B, Xi B, et al.: Intracerebral microdialysis for determination of the neuropharmacokinetics and neuropharmacodynamics of temozolomide in patients with primary or metastatic brain tumors [abstract]. J Clin Oncol 2007, **25:**2074. Google Scholar
Bergenheim AT, Roslin M, Ungerstedt U, et al.: Metabolic manipulation of glioblastoma in vivo by retrograde microdialysis of L-2, 4 diaminobutyric acid (DAB). J Neurooncol 2006, **80:**285–293. ArticlePubMedCAS Google Scholar
Mishani E, Abourbeh G: Cancer molecular imaging: radionuclide-based biomarkers of the epidermal growth factor receptor (EGFR). Curr Top Med Chem 2007, **7:**1755–1772. ArticlePubMedCAS Google Scholar
Sharma V, Prior JL, Belinsky MG, et al.: Characterization of a 67Ga/68Ga radiopharmaceutical for SPECT and PET of MDR1 P-glycoprotein transport activity in vivo: validation in multidrug-resistant tumors and at the blood-brain barrier. J Nucl Med 2005, **46:**354–364. PubMedCAS Google Scholar
Wu GN, Ford JM, Alger JR: MRI measurement of the uptake and retention of motexafin gadolinium in glioblastoma multiforme and uninvolved normal human brain. J Neurooncol 2006, **77:**95–103. ArticlePubMedCAS Google Scholar
Batchelor TT, Sorensen AG, di Tomaso E, et al.: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, **11:**83–95. ArticlePubMedCAS Google Scholar